Biofrontera Inc. - SIC # 3840 -

Ticker Exchange SIC # Website Latest Ticker
BFRI Nasdaq 3840 www.biofrontera-us.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Biofrontera Inc.

Pelthos Therapeutics Acquires Xepi® (ozenoxacin) Cream, 1% and Announces $18 Million Private Convertible Notes Financing - Nov 7th, 2025 6:00 am
Biofrontera Inc. announces sale of license to Xepi® Antibiotic Cream to Pelthos Therapeutics Inc. for up to $10M - Nov 7th, 2025 6:00 am
Lifecore Biomedical (LFCR) Reports Q1 Loss, Beats Revenue Estimates - Nov 6th, 2025 3:40 pm
Biofrontera Inc. to Report Third Quarter 2025 Financial Results on November 12, 2025 and Host a Conference Call on November 13, 2025 - Nov 6th, 2025 2:01 pm
Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Tops Revenue Estimates - Nov 5th, 2025 6:20 am
PTC Therapeutics (PTCT) Q3 Earnings and Revenues Top Estimates - Nov 4th, 2025 3:25 pm
Biofrontera Inc. close purchase of all Ameluz, RhodoLED U.S. assets - Oct 24th, 2025 6:55 am
Biofrontera Inc. Closes Purchase of All Ameluz® and RhodoLED® US Assets from Biofrontera AG - Oct 23rd, 2025 6:45 am
Biofrontera Inc. (NASDAQ:BFRI): When Will It Breakeven? - Sep 28th, 2025 8:17 am
Biofrontera Inc. to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025 - Sep 26th, 2025 7:15 am
Biofrontera Inc. Engages Lytham Partners to Lead Strategic Investor Relations and Shareholder Communication Program - Sep 23rd, 2025 7:20 am
Biofrontera Inc. Announces Last Patient Out in Phase 3 Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% Photodynamic Therapy (PDT) for the Treatment of Actinic Keratoses (AK) on the Extremities, Neck and Trunk - Sep 16th, 2025 8:30 am
Biofrontera Inc. Announces Last-Patient-Out in Phase 2b Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Moderate to Severe Acne Vulgaris - Aug 25th, 2025 6:25 am
Biofrontera Inc (BFRI) Q2 2025 Earnings Call Highlights: Record Revenue Growth Amid Operational ... - Aug 15th, 2025 1:20 am
Biofrontera Inc. Reports Second Quarter 2025 Financial Results and Provides a Business Update - Aug 13th, 2025 3:20 pm
Biofrontera Inc. Appoints George Jones as Chief Commercial Officer - Aug 11th, 2025 2:25 pm
Pacific Biosciences of California (PACB) Reports Q2 Loss, Beats Revenue Estimates - Aug 7th, 2025 5:00 pm
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q2 Loss, Tops Revenue Estimates - Aug 6th, 2025 4:00 pm
Biofrontera Inc. to Report Second Quarter FY 2025 Financial Results on August 13, 2025 - Aug 4th, 2025 12:00 pm
Biofrontera Inc. Announces Major Restructuring of Relationship With Biofrontera AG Backed By $11 Million Investment - Jun 30th, 2025 6:00 am